<ul>
<li>CRSPR 股票可能準備兑現其巨大的承諾</li>
</ul>
<p>CRISPR Therapeutics AG (NASDAQ:CRSP - 免費報告) - Cantor Fitzgerald 的股票研究分析師在 11 月 11 日星期二向客户和投資者發佈的研究報告中上調了對 CRISPR Therapeutics 2026 財年的收益預期。Cantor Fitzgerald 分析師 E. Schmidt 現在預計該公司將發佈每股收益（$6.22），高於之前預測的（$6.71）。CRISPR Therapeutics 當前全年的共識收益預期為每股（$5.16）。</p>
<p>其他幾位股票分析師最近也對 CRSP 發佈了報告。Needham &amp; Company LLC 將 CRISPR Therapeutics 的目標價格從$81.00 下調至$80.00，並在週一的研究報告中給予該公司 “買入” 評級。Wells Fargo &amp; Company 在 10 月 13 日的研究報告中對 CRISPR Therapeutics 設定了$75.00 的目標價格。HC Wainwright 在 9 月 23 日的研究報告中重申了 “買入” 評級，並對 CRISPR Therapeutics 設定了$80.00 的目標價格。Robert W. Baird 在週二的報告中將 CRISPR Therapeutics 的目標價格從$52.00 下調至$44.00，並對該股票給予 “中性” 評級。最後，Zacks Research 在 8 月 26 日的研究報告中將 CRISPR Therapeutics 的評級從 “強烈賣出” 上調至 “持有”。共有 11 位股票研究分析師對該股票給予 “買入” 評級，8 位給予 “持有” 評級，2 位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的當前共識評級為 “持有”，平均目標價格為$67.84。</p>
<p>獲取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
<ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
<p><strong>獲取我們最新的 CRSP 股票分析</strong></p>
<h2>CRISPR Therapeutics 股價下跌 3.1%</h2>
<p>CRSP 股票在週四的交易時段下跌$1.60，達到$50.59。該公司 745,808 股股票被交易，較其平均交易量 2,550,948 有所減少。CRISPR Therapeutics 的 1 年最低價為$30.04，1 年最高價為$78.48。該股票的 50 日移動平均價格為$63.02，200 日移動平均價格為$53.44。該股票的市值為$48.2 億，市盈率為-9.09，貝塔值為 1.89。</p>
<ul>
<li>2 只基因編輯股票在 2025 年有強勁反彈的潛力</li>
</ul>
<p>CRISPR Therapeutics (NASDAQ:CRSP - 獲取免費報告) 最近在 11 月 10 日星期一發布了季度收益數據。該公司報告的每股收益為（$1.17），超過分析師的共識預期（$1.32）$0.15。CRISPR Therapeutics 的淨利潤率為-1,273.70%，股本回報率為-21.23%。該公司本季度的收入為$0.89 百萬，而分析師預期為$8.74 百萬。</p>
<h2>機構資金流入和流出</h2>
<p>對沖基金和其他機構投資者最近買賣了該公司的股票。SVB Wealth LLC 在第一季度購買了 CRISPR Therapeutics 的新股份，價值約$25,000。Costello Asset Management INC 在第一季度購買了 CRISPR Therapeutics 的新股份，價值約$27,000。Atlantic Union Bankshares Corp 在第二季度購買了 CRISPR Therapeutics 的新股份，價值$33,000。Thompson Investment Management Inc.在第三季度購買了 CRISPR Therapeutics 的新股份，價值約$33,000。最後，Optiver Holding B.V.在第三季度將其在 CRISPR Therapeutics 的股份增加了 71.4%。Optiver Holding B.V.現在擁有該公司 504 股股票，價值$33,000，此前在上個季度又購買了 210 股。對沖基金和其他機構投資者持有該公司 69.20% 的股份。</p>
<h2>內部人士下注</h2>
<p>在相關消息中，首席法律顧問 James R. Kasinger 在 10 月 14 日星期二出售了 1,076 股公司的股票。股票以平均價格$66.60 出售，總價值為$71,661.60。出售完成後，首席法律顧問直接持有該公司 83,402 股股票，價值約$5,554,573.20。這筆交易代表其持股減少了 1.27%。該交易在向 SEC 提交的文件中披露，SEC 網站上可以訪問。此外，首席執行官 Samarth Kulkarni 在 10 月 17 日星期五出售了 50,895 股公司的股票。股票以平均價格$67.91 出售，總交易額為$3,456,279.45。交易完成後，首席執行官直接持有該公司 254,201 股股票，價值約$17,262,789.91。這代表其持股減少了 16.68%。該交易的披露可在 SEC 文件中找到。在上個季度，內部人士出售了 56,213 股公司股票，價值$3,810,458。公司內部人士持有該公司 4.30% 的股份。</p>
<h2>關於 CRISPR Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>CRISPR Therapeutics 是一家基因編輯公司，專注於利用其專有的 CRISPR/Cas9 平台開發針對嚴重疾病的變革性基因治療藥物。CRISPR/Cas9 是一項革命性的基因編輯技術，允許對基因組 DNA 進行精確、定向的更改。CRISPR Therapeutics 在包括血紅蛋白病、腫瘤學、再生醫學和罕見疾病等廣泛疾病領域建立了一系列治療項目。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票比 CRISPR Therapeutics 更好</li>
<li>10 只最佳航空公司股票</li>
<li>AMD 到$300 看起來很容易——這是為什麼$500 可能是下一個</li>
<li>我在哪裏可以找到 52 周的高點和低點？</li>
<li>超過$50 億的回購：DraftKings、AppLovin 和 Altria 在告訴你什麼</li>
<li>公用事業股票解析——如何以及為什麼投資公用事業</li>
<li>4 只高收益房地產股票，適合投資者採取防禦性策略</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 CRISPR Therapeutics 嗎？</h2>
<p>在考慮 CRISPR Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 CRISPR Therapeutics 並不在名單上。</p>
<p>雖然 CRISPR Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CRISPR治療

<p>Cantor Fitzgerald 分析師已上調 CRISPR Therapeutics 2026 財年的盈利預期，預測每股損失將小於之前預期。該股票的共識評級為 “持有”，平均目標價為 67.84 美元。最近的交易中，股價下跌了 3.1%，至 50.59 美元。機構投資者活躍，報告了顯著的內部交易。儘管公司的最近季度盈利超出預期，但淨利潤率和股本回報率均為負值</p>

<ul>
<li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li>
</ul>
<div class="lb-trans"><ul>
<li>CRSPR 股票可能準備兑現其巨大的承諾</li>
</ul>
</div><p>CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2026 earnings estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, November 11th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings per share of ($6.22) for the year, up from their prior forecast of ($6.71). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.</p>
<div class="lb-trans"><p>CRISPR Therapeutics AG (NASDAQ:CRSP - 免費報告) - Cantor Fitzgerald 的股票研究分析師在 11 月 11 日星期二向客户和投資者發佈的研究報告中上調了對 CRISPR Therapeutics 2026 財年的收益預期。Cantor Fitzgerald 分析師 E. Schmidt 現在預計該公司將發佈每股收益（$6.22），高於之前預測的（$6.71）。CRISPR Therapeutics 當前全年的共識收益預期為每股（$5.16）。</p>
</div><p>Several other equities analysts have also recently issued reports on CRSP. Needham &amp; Company LLC decreased their target price on shares of CRISPR Therapeutics from $81.00 to $80.00 and set a &#34;buy&#34; rating for the company in a research note on Monday. Wells Fargo &amp; Company set a $75.00 price target on shares of CRISPR Therapeutics in a research report on Monday, October 13th. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, September 23rd. Robert W. Baird dropped their price objective on CRISPR Therapeutics from $52.00 to $44.00 and set a &#34;neutral&#34; rating on the stock in a report on Tuesday. Finally, Zacks Research upgraded shares of CRISPR Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, August 26th. Eleven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and an average price target of $67.84.</p>
<div class="lb-trans"><p>其他幾位股票分析師最近也對 CRSP 發佈了報告。Needham &amp; Company LLC 將 CRISPR Therapeutics 的目標價格從$81.00 下調至$80.00，並在週一的研究報告中給予該公司 “買入” 評級。Wells Fargo &amp; Company 在 10 月 13 日的研究報告中對 CRISPR Therapeutics 設定了$75.00 的目標價格。HC Wainwright 在 9 月 23 日的研究報告中重申了 “買入” 評級，並對 CRISPR Therapeutics 設定了$80.00 的目標價格。Robert W. Baird 在週二的報告中將 CRISPR Therapeutics 的目標價格從$52.00 下調至$44.00，並對該股票給予 “中性” 評級。最後，Zacks Research 在 8 月 26 日的研究報告中將 CRISPR Therapeutics 的評級從 “強烈賣出” 上調至 “持有”。共有 11 位股票研究分析師對該股票給予 “買入” 評級，8 位給予 “持有” 評級，2 位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的當前共識評級為 “持有”，平均目標價格為$67.84。</p>
</div><p>Get <strong>CRISPR Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on CRSP</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 CRSP 股票分析</strong></p>
</div><h2>CRISPR Therapeutics Trading Down 3.1%</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 股價下跌 3.1%</h2>
</div><p>Shares of CRSP stock traded down $1.60 during trading hours on Thursday, reaching $50.59. 745,808 shares of the company's stock were exchanged, compared to its average volume of 2,550,948. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $78.48. The stock's fifty day moving average price is $63.02 and its two-hundred day moving average price is $53.44. The stock has a market cap of $4.82 billion, a PE ratio of -9.09 and a beta of 1.89.</p>
<div class="lb-trans"><p>CRSP 股票在週四的交易時段下跌$1.60，達到$50.59。該公司 745,808 股股票被交易，較其平均交易量 2,550,948 有所減少。CRISPR Therapeutics 的 1 年最低價為$30.04，1 年最高價為$78.48。該股票的 50 日移動平均價格為$63.02，200 日移動平均價格為$53.44。該股票的市值為$48.2 億，市盈率為-9.09，貝塔值為 1.89。</p>
</div><ul>
<li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因編輯股票在 2025 年有強勁反彈的潛力</li>
</ul>
</div><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping analysts' consensus estimates of ($1.32) by $0.15. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $8.74 million.</p>
<div class="lb-trans"><p>CRISPR Therapeutics (NASDAQ:CRSP - 獲取免費報告) 最近在 11 月 10 日星期一發布了季度收益數據。該公司報告的每股收益為（$1.17），超過分析師的共識預期（$1.32）$0.15。CRISPR Therapeutics 的淨利潤率為-1,273.70%，股本回報率為-21.23%。該公司本季度的收入為$0.89 百萬，而分析師預期為$8.74 百萬。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. SVB Wealth LLC purchased a new stake in CRISPR Therapeutics during the first quarter valued at about $25,000. Costello Asset Management INC bought a new stake in CRISPR Therapeutics during the first quarter valued at approximately $27,000. Atlantic Union Bankshares Corp bought a new position in CRISPR Therapeutics in the second quarter valued at $33,000. Thompson Investment Management Inc. purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at about $33,000. Finally, Optiver Holding B.V. boosted its stake in shares of CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company's stock valued at $33,000 after purchasing an additional 210 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近買賣了該公司的股票。SVB Wealth LLC 在第一季度購買了 CRISPR Therapeutics 的新股份，價值約$25,000。Costello Asset Management INC 在第一季度購買了 CRISPR Therapeutics 的新股份，價值約$27,000。Atlantic Union Bankshares Corp 在第二季度購買了 CRISPR Therapeutics 的新股份，價值$33,000。Thompson Investment Management Inc.在第三季度購買了 CRISPR Therapeutics 的新股份，價值約$33,000。最後，Optiver Holding B.V.在第三季度將其在 CRISPR Therapeutics 的股份增加了 71.4%。Optiver Holding B.V.現在擁有該公司 504 股股票，價值$33,000，此前在上個季度又購買了 210 股。對沖基金和其他機構投資者持有該公司 69.20% 的股份。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In related news, General Counsel James R. Kasinger sold 1,076 shares of the firm's stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the completion of the sale, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. This trade represents a 1.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 50,895 shares of the firm's stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares in the company, valued at approximately $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 56,213 shares of company stock valued at $3,810,458. Corporate insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席法律顧問 James R. Kasinger 在 10 月 14 日星期二出售了 1,076 股公司的股票。股票以平均價格$66.60 出售，總價值為$71,661.60。出售完成後，首席法律顧問直接持有該公司 83,402 股股票，價值約$5,554,573.20。這筆交易代表其持股減少了 1.27%。該交易在向 SEC 提交的文件中披露，SEC 網站上可以訪問。此外，首席執行官 Samarth Kulkarni 在 10 月 17 日星期五出售了 50,895 股公司的股票。股票以平均價格$67.91 出售，總交易額為$3,456,279.45。交易完成後，首席執行官直接持有該公司 254,201 股股票，價值約$17,262,789.91。這代表其持股減少了 16.68%。該交易的披露可在 SEC 文件中找到。在上個季度，內部人士出售了 56,213 股公司股票，價值$3,810,458。公司內部人士持有該公司 4.30% 的股份。</p>
</div><h2>About CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>關於 CRISPR Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 是一家基因編輯公司，專注於利用其專有的 CRISPR/Cas9 平台開發針對嚴重疾病的變革性基因治療藥物。CRISPR/Cas9 是一項革命性的基因編輯技術，允許對基因組 DNA 進行精確、定向的更改。CRISPR Therapeutics 在包括血紅蛋白病、腫瘤學、再生醫學和罕見疾病等廣泛疾病領域建立了一系列治療項目。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than CRISPR Therapeutics</li>
<li>10 Best Airline Stocks to Buy</li>
<li>AMD to $300 Looks Easy—Here’s Why $500 Could Be Next</li>
<li>Where Do I Find 52-Week Highs and Lows?</li>
<li>$5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You</li>
<li>Utilities Stocks Explained – How and Why to Invest in Utilities</li>
<li>4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 CRISPR Therapeutics 更好</li>
<li>10 只最佳航空公司股票</li>
<li>AMD 到$300 看起來很容易——這是為什麼$500 可能是下一個</li>
<li>我在哪裏可以找到 52 周的高點和低點？</li>
<li>超過$50 億的回購：DraftKings、AppLovin 和 Altria 在告訴你什麼</li>
<li>公用事業股票解析——如何以及為什麼投資公用事業</li>
<li>4 只高收益房地產股票，適合投資者採取防禦性策略</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 CRISPR Therapeutics 嗎？</h2>
</div><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CRISPR Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 CRISPR Therapeutics 並不在名單上。</p>
</div><p>While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CRISPR Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

股票分析師發佈了對 CRSP 2026 財年收益的預測